# Phase 1 Lymphoma, B-Cell, Marginal Zone trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 1 for Lymphoma, B-Cell, Marginal Zone that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lymphoma, B-Cell, Marginal Zone trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma-b-cell-marginal-zone

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| August 14, 2025 | NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | LTZ Therapeutics, Inc. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL)... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07121946) |
| August 3, 2025 | NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF\_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell... | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101328) |
| June 17, 2025 | NCT07024147 | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma | Peking University Cancer Hospital & Institute | Phase 1 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma, Mantle... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024147) |
| May 20, 2025 | NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980116) |
| March 5, 2025 | NCT06859008 | Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory... | City of Hope Medical Center | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859008) |
| December 2, 2024 | NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | Mayo Clinic | Phase 1 | Recruiting | Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712810) |
| November 27, 2024 | NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | Lomond Therapeutics Holdings, Inc. | Phase 1 | Recruiting | CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06708897) |
| August 9, 2024 | NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | Verismo Therapeutics | Phase 1 | Recruiting | B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06544265) |
| April 1, 2024 | NCT06340737 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | Stanford University | Phase 1 | Recruiting | Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma, Marginal... | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06340737) |
| January 5, 2024 | NCT06191887 | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for... | Mayo Clinic | Phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191887) |
| September 7, 2023 | NCT06026319 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06026319) |
| August 14, 2023 | NCT05990465 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | Medical College of Wisconsin | Phase 1 | Recruiting | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05990465) |
| March 22, 2023 | NCT05780034 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Accutar Biotechnology Inc | Phase 1 | Recruiting | Relapsed/Refractory B-cell Malignancies | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05780034) |
| November 2, 2022 | NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Carna Biosciences, Inc. | Phase 1 | Recruiting | B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05602363) |
| September 16, 2022 | NCT05544019 | Study of SGR-1505 in Mature B-Cell Neoplasms | Schrödinger, Inc. | Phase 1 | Recruiting | Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma... | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05544019) |
| November 23, 2021 | NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular... | 572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05131022) |
| April 2, 2021 | NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Nurix Therapeutics, Inc. | Phase 1 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell... | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04830137) |
| March 1, 2021 | NCT04775745 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Newave Pharmaceutical Inc | Phase 1 | Recruiting | CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04775745) |
| September 11, 2020 | NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04545762) |
| January 10, 2020 | NCT04223765 | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+... | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Recruiting | Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04223765) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Nurix Therapeutics, Inc. | 2 |
| Mayo Clinic | 2 |
| Medical College of Wisconsin | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| LTZ Therapeutics, Inc. | 1 |
| Lomond Therapeutics Holdings, Inc. | 1 |
| [Ascentage Pharma Group Inc.](https://specstream.ai/data/clinical-trials/company/ascentage-pharma-group-inc) | 1 |
| Verismo Therapeutics | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Accutar Biotechnology Inc | 1 |
| City of Hope Medical Center | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |
| Schrödinger, Inc. | 1 |
| Stanford University | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| Carna Biosciences, Inc. | 1 |
| Newave Pharmaceutical Inc | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 21 |
| Poland | 5 |
| Spain | 5 |
| France | 4 |
| Italy | 4 |
| United Kingdom | 3 |
| China | 2 |
| Australia | 2 |
| Moldova | 2 |
| Ukraine | 2 |
| Netherlands | 1 |
| Switzerland | 1 |
| Romania | 1 |
| Georgia | 1 |
| Greece | 1 |
| Canada | 1 |
| Denmark | 1 |
| Germany | 1 |
| Japan | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
- [B2B secretarial companies in the United States](https://specstream.ai/data/businesses/b2b-secretarial-companies/united-states)
- [Janitorial companies in the United States](https://specstream.ai/data/businesses/janitorial-companies/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
